Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of neoadjuvant chemotherapy plus IMRT with cetuximab in advanced T-stage nasopharyngeal carcinoma
ChiCTR-TNC-11001145Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Acute toxicity and Efficacy at 3 months. Started Sep 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-TNC-11001145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-11001145.